Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
February 4, 2026
Immunology Today—February 4, 2026
February 4, 2026
Women’s Health Video Recap—February 4, 2026
February 4, 2026
Neuroscience Video Recap—February 4, 2026
February 4, 2026
Neuroscience Today—February 4, 2026
February 3, 2026
Endocrinology Today—February 3, 2026
February 3, 2026
Obesity Video Recap—February 3, 2026
February 3, 2026
Obesity Today—February 3, 2026
February 3, 2026
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA
February 2, 2026
Oncology Video Recap—February 2, 2026
February 2, 2026
AI in Healthcare and Digital Health Today—February 2, 2026
February 2, 2026